Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Apr 7, 2014

Roche Purchases Bolster the Firm’s Molecular Dx, Gene Regulation Capabilities

  • In an effort to strengthen its molecular diagnostics offerings, Roche has just nabbed Massachusetts-based firm IQuum, a company that develops point-of-care products for molecular diagnostics. Roche will pay IQuum shareholders $275 million upfront and up to $175 million in product-related milestones. IQuum will be folded into Roche Molecular Diagnostics once the merger is complete.

    With the acquisition, Roche is getting IQuum's Laboratory-in-a-tube (Liat™) System, which IQuum says allows healthcare workers to perform rapid molecular diagnostic testing in a point-of-care setting, along with the Liat Analyzer and Liat Influenza A/B Assay, the first test available for use on the system.

    But, that's not Roche's only big purchase today: The Swiss firm also inked a deal with Spanish firm Oryzon Genomics to research, develop, and commercialize inhibitors of lysine-specific demethylase-1 (LSD1; KDM1A), an epigenetic modulator that regulates gene expression. Among the inhibitors that are part of the deal is Oryzon's lead molecule ORY-1001, which right now is in a Phase I/IIa trial for acute myeloid leukemia.

    Per this deal, Roche is paying Oryzon $21 million upfront and for near-term milestones, plus potential milestone payments that could exceed $500 million across hematology, cancer, and nonmalignant indications. Roche will also pay royalties on sales that range up to mid-double digits. 

    A two-year collaborative research program between Oryzon and Roche’s Translational Clinical Research Center (TCRC) is also a part of the deal, the aim of which is to understand the potential of LSD1 inhibitors in oncology and hematology.

    "Our TCRC in New York has been launched with a mandate to identify partnerships that drive innovation, providing an industry-leading conduit between sources of breakthrough science and the broader Roche organization," John Reed, Roche’s head of pharma research and early development, said in a statement. "This collaboration on LSD1 inhibition with Oryzon fulfills that mandate perfectly."

Related content


GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

What Does Brexit Mean for Biotech?

Do you agree with the contention that Brexit will NOT have a long-term negative impact on the British biotech industry?

More »